Folgen
Ranuk Ramachandra
Ranuk Ramachandra
University of Toronto, Toronto Metropolitan University, University Health Network
Bestätigte E-Mail-Adresse bei mail.utoronto.ca
Titel
Zitiert von
Zitiert von
Jahr
Glucagon-like peptide 1 (GLP-1) receptor agonists as a protective factor for incident depression in patients with diabetes mellitus: A systematic review
DH Cooper, R Ramachandra, F Ceban, JD Di Vincenzo, TG Rhee, ...
Journal of Psychiatric Research 164, 80-89, 2023
282023
Vortioxetine for the treatment of post-COVID-19 condition: a randomized controlled trial
RS McIntyre, L Phan, ATH Kwan, RB Mansur, JD Rosenblat, Z Guo, ...
Brain 147 (3), 849-857, 2024
262024
The bidirectional association of nonalcoholic fatty liver disease with depression, bipolar disorder, and schizophrenia
MY Jawad, S Meshkat, A Tabassum, A Mckenzie, JD Di Vincenzo, Z Guo, ...
CNS spectrums 28 (5), 541-560, 2023
212023
Efficacy, safety, and tolerability of ulotaront (SEP-363856, a trace amine-associated receptor 1 agonist) for the treatment of schizophrenia and other mental disorders: a …
GH Le, ES Gillissie, TG Rhee, B Cao, Y Alnefeesi, Z Guo, JD Di Vincenzo, ...
Expert Opinion on Investigational Drugs 32 (5), 401-415, 2023
132023
Efficacy, safety, and tolerability of xanomeline for schizophrenia spectrum disorders: a systematic review
A Leber, R Ramachandra, F Ceban, ATH Kwan, TG Rhee, J Wu, B Cao, ...
Expert Opinion on Pharmacotherapy 25 (4), 467-476, 2024
82024
Vortioxetine for the Treatment of Post-COVID-19 Condition: A Randomized Controlled Trial (S28. 001)
A Kwan, L Phan, R Mansur, J Rosenblat, Z Guo, GH Le, K Teopiz, ...
Neurology 102 (17_supplement_1), 1234, 2024
2024
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–6